Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

UBS's Kevin Caliendo raised their price target on Mckesson (NYSE: MCK) by 5% from $1,000 to $1,050 on 2026/05/09. The analyst maintained their Strong Buy rating on the stock.

McKesson reported its Q4 and FY 2026 earnings.

Following an assessment of the print, Caliendo said the "messy" Q4 results did not affect their bullish view because management's initial FY 2027 guidance was "good enough."

Earnings Report

McKesson reported:

For Q4 2026:

• EPS of $11.69, which beat the Zacks Consensus Estimate of $11.56 and, by 16%, Q4 2025’s $10.12.
• Revenue of $96.3B, which missed the Zacks Consensus Estimate by 5.52% but beat, by 6%, Q4 2025’s $90.82B.

For FY 2026:

• EPS of $39.11, up 18% Y/Y.
• Revenue of $403.4B, up 12% Y/Y.

For FY 2027, management guided:

• EPS of $43.80 to $44.60.

CEO Brian Tyler commented: “McKesson’s Q4 results reflect the strength of our diversified portfolio and disciplined 

execution against our strategic priorities. 

“Our FY performance, headlined by 12% revenue growth and 18% adjusted EPS growth, exceeded our long-range growth targets and demonstrates our ability to consistently deliver growth and operating leverage across the enterprise.

“We delivered significant progress - expanding specialty provider support, accelerating patient access through our scaled and integrated biopharma support services, and continuing to optimize our portfolio through the divestiture of Europe and the planned separation of our Medical-Surgical business. 

“These accomplishments are a direct result of the talent and operational excellence of our employees, and I want to thank Team McKesson for their continued dedication throughout the year.

“Looking ahead to FY 2027, we are well-positioned to build upon this momentum.

“We remain committed to executing with discipline across the portfolio, investing in high-growth and high-margin areas in Oncology and Biopharma Services. 

“By combining our operating execution with a more focused and optimized portfolio, we will continue to deliver sustainable growth and create long-term value for our shareholders.”